Pediatr Nephrol
Pediatric Nephrology (Berlin, Germany)
0931-041X
1432-198X
Springer-Verlag
Berlin/Heidelberg


1805051
17206511
405
10.1007/s00467-006-0405-y
Review


Iron therapy for renal anemia: how much needed, how much harmful?

Hörl
Walter H.

+43-1-404004390
+43-1-404004392
walter.hoerl@meduniwien.ac.at



Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria 

6
1
2007

4
2007

22
4
480
489
6
7
2006

13
11
2006

14
11
2006


© IPNA 2007

Iron deficiency is the most common cause of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in end-stage renal disease (ESRD) patients. Iron deficiency can easily be corrected by intravenous iron administration, which is more effective than oral iron supplementation, at least in adult patients with chronic kidney disease (CKD). Iron status can be monitored by different parameters such as ferritin, transferrin saturation, percentage of hypochromic red blood cells, and/or the reticulocyte hemoglobin content, but an increased erythropoietic response to iron supplementation is the most widely accepted reference standard of iron-deficient erythropoiesis. Parenteral iron therapy is not without acute and chronic adverse events. While provocative animal and in vitro studies suggest induction of inflammation, oxidative stress, and kidney damage by available parenteral iron preparations, several recent clinical studies showed the opposite effects as long as intravenous iron was adequately dosed. Thus, within the recommended international guidelines, parenteral iron administration is safe. Intravenous iron therapy should be withheld during acute infection but not during inflammation. The integration of ESA and intravenous iron therapy into anemia management allowed attainment of target hemoglobin values in the majority of pediatric and adult CKD and ESRD patients.

Keywords
Iron supplementation
Iron status
Inflammation
Infection
Erythropoiesis-stimulating agents

issue-copyright-statement
© IPNA 2007




Introduction
Inadequate intake of dietary iron

Blood loss during the extracorporeal procedure in hemodialysis patients

Blood loss from the gastrointestinal tract (bleeding)

(Too) frequent diagnostic blood tests

Inadequate intestinal iron absorption and inhibition of iron release from macrophages (anemia of chronic disease)

Increased iron requirements during therapy with erythropoiesis-stimulating agents (ESAs).



In iron deficiency without anemia, reduction in iron storage is not sufficiently large enough to decrease the hemoglobin level. In CKD patients with absolute iron-deficient anemia, however, iron deficit is so severe that it aggravates renal anemia. Iron supplementation is mandatory in the majority of patients with end-stage renal disease (ESRD), particularly in those receiving ESA therapy.

Evaluation of iron status
1
2
1
3
4
5
2
6
7
8
9
10
].
11
12
13
14
8
15
16
]. In children with ESRD, an increase from baseline CHr levels was observed in response to oral and intravenous iron, but cut-off values for the use of CHr in the pediatric CKD population are not clear. This measure has proven to be of value with adult ESRD patients.
Detection of both absolute and functional iron deficiency is important because iron deficiency is the most common cause of hyporesponsiveness to ESAs. In clinical practice, an increased erythropoietic response to iron supplementation is the most widely accepted reference standard of iron-deficient erythropoiesis. For pharmacological therapy of iron deficiency, both oral and parenteral iron preparations are available. Intravenous iron is more effective than oral iron supplementation, at least in CKD patients. Iron is not only a prerequisite for effective erythropoiesis but also an essential element in all living cells. Elemental iron serves as a component of oxygen-carrying molecules and as a cofactor for enzymatic processes. Its redox potential, however, limits the quantity of iron that can be safely harbored within an individual.

Oral iron therapy
17
18
19
].
20
21
22
23
].
3+
2+
2+
24
25
].
18
26
].

Intravenous iron therapy
27
34
1
2
35
1
2
36
37
32
34
38
29
39
2
]. It should be considered that the iron load administered intravenously to CKD patients based on international recommendations is more than ten times less than the iron load by repeated blood transfusions at times when no ESA therapy was available for ESRD patients.
40
1
41
].
42
42
43
].
16
16
44
45
46
3
4
47
48
49
50
].
51
52
53
].

Iron and inflammation/infection
54
55
56
].
55
55
56
].
55
57
58
58
59
60
61
]. All these data suggest a risk for infectious complications, at least in patients overtreated with iron.
62
64
64
65
65
]. However, a clinical problem is the diagnosis of chronic anemia associated with inflammation and true iron deficiency, as serum ferritin concentration increases rather than decreases.

Iron and kidney function
37
66
67
68
69
70
2
2
70
71
] found that a single dose of 100 mg iron sucrose results in a transient increase of MCP-1 in plasma and urine of CKD patients. Those who believe that 100 mg iron sucrose administered to CKD patients may negatively affect kidney function should simply administer a lower intravenous iron dose, e.g., 50 mg iron sucrose intravenously.

Iron and oxidative stress
72
70
] demonstrated that intravenous iron sucrose therapy administered within international recommendations (none of the 58 CKD patients exceeded serum ferritin of 500 μg/l) does not cause a decline in kidney function in CKD patients over a period of 1 year.
73
75
75
76
2
77
78
37
59
79
80
]. Whether intravenous iron therapy results in an additional oxidative stress reaction needs to be further evaluated.
79
81
82
82
].

Vitamin C and iron
83
84
85
86
87
88
89
].
90
91
92
93
99
100
]. Studies on vitamin C and iron in children with ESRD are not available so far.

Iron therapy after kidney transplantation
101
104
105
106
107
108
109
].

Conclusions
110
110
].


References
1.
Locatelli
F

Aljama
P

Barany
P

Canaud
B

Carrera
F

Eckardt
KU

Hörl
WH

Macdougall
IC

Macleod
A

Wiecek
A

Cameron
S

European Best Practice Guidelines Working Group

Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure
Nephrol Dial Transplant
2004
19
Suppl 2
ii1
ii47

15206425


2.
K/DOQI
National Kidney Foundation

Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease
Am J Kidney Dis
2006
47
5 Suppl 3
S11
S145

16678659


3.
Tenbrock
K

Muller-Berghaus
J

Michalk
D

Querfeld
U


Intravenous iron treatment of renal anemia in children on hemodialysis
Pediatr Nephrol
1999
13
580
582

10460505


4.
Greenbaum
LA

Pan
CG

Caley
C

Nelson
T

Sheth
KJ


Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients
Pediatr Nephrol
2000
14
908
911

10975297


5.
Morris
KP

Watson
S

Reid
MM

Hamilton
PJ

Coulthard
MG


Assessing iron status in children with chronic renal failure on erythropoietin: which measurements should we use?
Pediatr Nephrol
1994
8
51
56

8142226


6.
Brugnara
C


Iron deficiency and erythropoiesis: new diagnostic approaches
Clin Chem
2003
49
1573
1578

14500582


7.
Chiang
WC

Tsai
TJ

Chen
YM

Lin
SL

Hsieh
BS


Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients
Clin Nephrol
2002
58
363
369

12425487


8.
Weiss
G

Gordeuk
VR


Benefits and risks of iron therapy for chronic anaemias
Eur J Clin Invest
2005
35
Suppl 3
36
45

16281957


9.
Chuang
CL

Liu
RS

Wei
YH

Huang
TP

Tarng
DC


Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients
Nephrol Dial Transplant
2003
18
370
377

12543894


10.
Besarab
A


Evaluating iron sufficiency: a clearer view
Kidney Int
2001
60
2412
2414

11737618


11.
Macdougall
IC

Cavill
I

Hulme
B

Bain
B

McGregor
E

McKay
P

Sanders
E

Coles
GA

Williams
JD


Detection of functional iron deficiency during erythropoietin treatment: a new approach
BMJ
1992
304
225
226

1739797


12.
Tessitore
N

Solero
GP

Lippi
G

Bassi
A

Faccini
GB

Bedogna
V

Gammaro
L

Brocco
G

Restivo
G

Bernich
P

Lupo
A

Maschio
G


The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin
Nephrol Dial Transplant
2001
16
1416
1423

11427634


13.
Fishbane
S

Galgano
C

Langley
RC

Canfield
W

Maesaka
JK


Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients
Kidney Int
1997
52
217
222

9211366


14.
Mittman
N

Sreedhara
R

Mushnick
R

Chattopadhyay
J

Zelmanovic
D

Vaseghi
M

Avram
MM


Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO
Am J Kidney Dis
1997
30
912
922

9398141


15.
Warady
BA

Kausz
A

Lerner
G

Brewer
ED

Chadha
V

Brugnara
C

Dahl
NV

Watkins
SL


Iron therapy in the pediatric hemodialysis population
Pediatr Nephrol
2004
19
655
661

15064942


16.
Warady
BA

Zobrist
RH

Wu
J

Finan
E

Ferrlecit Pediatric Study Group

Sodium ferric gluconate complex therapy in anemic children on hemodialysis
Pediatr Nephrol
2005
20
1320
1327

15971073


17.
Damme-Lombaerts
R

Herman
J


Erythropoietin treatment in children with renal failure
Pediatr Nephrol
1999
13
148
152

10229005


18.
Schroder
CH

European Pediatric Peritoneal Dialysis Working Group

The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee
Pediatr Nephrol
2003
18
805
809

12750985


19.
Devasthali
SD

Gordeuk
VR

Brittenham
GM

Bravo
JR

Hughes
MA

Keating
LJ


Bioavailability of carbonyl iron: a randomized, double-blind study
Eur J Haematol
1991
46
272
278

2044721


20.
Kimmel
PL

Phillips
TM

Simmens
SJ

Peterson
RA

Weihs
KL

Alleyne
S

Cruz
I

Yanovski
JA

Veis
JH


Immunologic function and survival in hemodialysis patients
Kidney Int
1998
54
236
244

9648084


21.
Bergström
J

Lindholm
B

Lacson
E

Owen
W

Lowrie
EG

Glassock
RJ

Ikizler
TA

Wessels
FJ

Moldawer
LL

Wanner
C

Zimmermann
J


What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients?
Semin Dial
2000
13
163
175

10833777


22.
Kaysen
GA


The microinflammatory state in uremia: causes and potential consequences
J Am Soc Nephrol
2001
12
1549
1557

11423586


23.
Deicher
R

Hörl
WH


Hepcidin: a molecular link between inflammation and anaemia
Nephrol Dial Transplant
2004
19
521
524

14767000


24.
Deicher
R

Hörl
WH


New insights into the regulation of iron homeostasis
Eur J Clin Invest
2006
36
301
309

16634833


25.
Dittrich
E

Puttinger
H

Schneider
B

Hörl
WH

Haag-Weber
M

Vychytil
A


Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients?
Perit Dial Int
2000
20
667
673

11216557


26.
Neu
AM

Ho
PL

McDonald
RA

Warady
BA


Chronic dialysis in children and adolescents. The 2001 NAPRTCS Annual Report
Pediatr Nephrol
2002
17
656
663

12185477


27.
Sunder-Plassmann
G

Hörl
WH


Safety aspects of parenteral iron in patients with end-stage renal disease
Drug Saf
1997
17
241
250

9352960


28.
Fishbane
S

Kowalski
EA


The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate
Semin Dial
2000
13
381
384

11130261


29.
Wyck
DB

Cavallo
G

Spinowitz
BS

Adhikarla
R

Gagnon
S

Charytan
C

Levin
N


Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial
Am J Kidney Dis
2000
36
88
97

10873877


30.
Chandler
G

Harchowal
J

Macdougall
IC


Intravenous iron sucrose: establishing a safe dose
Am J Kidney Dis
2001
38
988
991

11684551


31.
Macdougall
IC

Roche
A


Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections
Am J Kidney Dis
2005
46
283
289

16112047


32.
Aronoff
GR

Bennett
WM

Blumenthal
S

Charytan
C

Pennell
JP

Reed
J

Rothstein
M

Strom
J

Wolfe
A

Wyck
D

Yee
J

United States Iron Sucrose (Venofer) Clinical Trials Group

Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens
Kidney Int
2004
66
1193
1198

15327417


33.
Chertow
GM

Mason
PD

Vaage-Nilsen
O

Ahlmen
J


On the relative safety of parenteral iron formulations
Nephrol Dial Transplant
2004
19
1571
1575

15150356


34.
Michael
B

Coyne
DW

Folkert
VW

Dahl
NV

Warnock
DG

Ferrlecit Publication Committee

Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety
Nephrol Dial Transplant
2004
19
1576
1580

15034152


35.
Wyck
DB

Roppolo
M

Martinez
CO

Mazey
RM

McMurray
S

for the United States Iron Sucrose (Venofer) Clinical Trials Group

A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD
Kidney Int
2005
68
2846
2856

16316362


36.
Bailie
GR

Clark
JA

Lane
CE

Lane
PL


Hypersensitivity reactions and deaths associated with intravenous iron preparations
Nephrol Dial Transplant
2005
20
1443
1449

15855210


37.
Agarwal
R

Vasavada
N

Sachs
NG

Chase
S


Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease
Kidney Int
2004
65
2279
2289

15149341


38.
Bailie
GR

Johnson
CA

Mason
NA


Parenteral iron use in the management of anemia in end-stage renal disease patients
Am J Kidney Dis
2000
35
1
12

10620537


39.
Coyne
DW

Adkinson
NF

Nissenson
AR

Fishbane
S

Agarwal
R

Eschbach
JW

Michael
B

Folkert
V

Batlle
D

Trout
JR

Dahl
N

Myirski
P

Strobos
J

Warnock
DG

Ferrlecit Investigators

Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients
Kidney Int
2003
63
217
224

12472786


40.
Hörl
WH

Vanrenterghem
Y

Canaud
B

Mann
J

Teatini
U

Wanner
C

Wikstrom
B


Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin
Nephrol Dial Transplant
2005
20
Suppl 3
iii25
iii32

15824127


41.
Weiss
G

Goodnough
LT


Anemia of chronic disease
N Engl J Med
2005
352
1011
1023

15758012


42.
Chavers
BM

Roberts
TL

Herzog
CA

Collins
AJ

Peter
WL


Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients
Kidney Int
2004
65
266
273

14675059


43.
Frankenfield
DL

Neu
AM

Warady
BA

Fivush
BA

Johnson
CA

Brem
AS


Anemia in pediatric hemodialysis patients: results from the 2001 ESRD Clinical Performance Measures Project
Kidney Int
2003
64
1120
1124

12911565


44.
Warady
BA

Zobrist
RH

Finan
E

Ferrlecit Pediatric Study Group

Sodium ferric gluconate complex maintenance therapy in children on hemodialysis
Pediatr Nephrol
2006
21
553
560

16520948


45.
Anbu
AT

Kemp
T

O’Donnell
K

Smith
PA

Bradbury
MG


Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin
Acta Paediatr
2005
94
1738
1741

16431410


46.
Ruiz-Jaramillo
M de L

Guizar-Mendoza
JM

Gutierrez-Navarrode
M de J

Dubey-Ortega
LA

Amador-Licona
N


Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study
Pediatr Nephrol
2004
19
77
81

14634860


47.
Morgan
HE

Gautam
M

Geary
DF


Maintenance intravenous iron therapy in pediatric hemodialysis patients
Pediatr Nephrol
2001
16
779
783

11605781


48.
Yorgin
PD

Belson
A

Sarwal
M

Alexander
SR


Sodium ferric gluconate therapy in renal transplant and renal failure patients
Pediatr Nephrol
2000
15
171
175

11149105


49.
Palo
T

Giordano
M

Palumbo
F

Bellantuono
R

Messina
G

Colella
V

Caringella
AD


Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis
Pediatr Nephrol
2004
19
337
340

14745634


50.
Gillespie
RS

Wolf
FM


Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis
Pediatr Nephrol
2004
19
662
666

15052462


51.
Agarwal
R

Warnock
D


Issues related to iron replacement in chronic kidney disease
Semin Nephrol
2002
22
479
487

12430092


52.
Besarab
A


Resolving the paradigm crisis in intravenous iron and erythropoietin management
Kidney Int
2006
69
S13
S18

Besarab A (2006) Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int 69:S13–S18 

53.
Peter
WL

Obrador
GT

Roberts
TL

Collins
AJ


Trends in intravenous iron use among dialysis patients in the United States (1994–2002)
Am J Kidney Dis
2005
46
650
660

16183420


54.
Zager
RA

Johnson
AC

Hanson
SY

Lund
S


Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release
Am J Physiol Renal Physiol
2005
288
F290
F297

15494544


55.
Weiss
G

Meusburger
E

Radacher
G

Garimorth
K

Neyer
U

Mayer
G


Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin
Kidney Int
2003
64
572
578

12846752


56.
Kaltwasser
JP

Kessler
U

Gottschalk
R

Stucki
G

Moller
B


Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis
J Rheumatol
2001
28
2430
2436

11708414


57.
Parkkinen
J

Bonsdorff
L

Peltonen
S

Gronhagen-Riska
C

Rosenlof
K


Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration
Nephrol Dial Transplant
2000
15
1827
1834

11071973


58.
Teehan
GS

Bahdouch
D

Ruthazer
R

Balakrishnan
VS

Snydman
DR

Jaber
BL


Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy
Clin Infect Dis
2004
38
1090
1094

15095212


59.
Patruta
SI

Edlinger
R

Sunder-Plassmann
G

Hörl
WH


Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency
J Am Soc Nephrol
1998
9
655
663

9555668


60.
Deicher
R

Ziai
F

Cohen
G

Müllner
M

Hörl
WH


High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity
Kidney Int
2003
64
728
736

12846772


61.
Sengoelge
G

Kletzmayr
J

Ferrara
I

Perschl
A

Hörl
WH

Sunder-Plassmann
G


Impairment of transendothelial leukocyte migration by iron complexes
J Am Soc Nephrol
2003
14
2639
2644

14514743


62.
Feldman
HI

Santanna
J

Guo
W

Furst
H

Franklin
E

Joffe
M

Marcus
S

Faich
G


Iron administration and clinical outcomes in hemodialysis patients
J Am Soc Nephrol
2002
13
734
744

11856779


63.
Hoen
B

Paul-Dauphin
A

Hestin
D

Kessler
M


EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients
J Am Soc Nephrol
1998
9
869
876

9596085


64.
Feldman
HI

Joffe
M

Robinson
B

Knauss
J

Cizman
B

Guo
W

Franklin-Becker
E

Faich
G


Administration of parenteral iron and mortality among hemodialysis patients
J Am Soc Nephrol
2004
15
1623
1632

15153574


65.
Agarwal
R


Overcoming barriers that inhibit proper treatment of anemia
Kidney Int
2006
69
S9
S12

Agarwal R (2006) Overcoming barriers that inhibit proper treatment of anemia. Kidney Int 69:S9–S12 

66.
Leehey
DJ

Palubiak
DJ

Chebrolu
S

Agarwal
R


Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study
Nephrol Dial Transplant
2005
20
135
140

15522899


67.
Baliga
R

Ueda
N

Shah
SV


Kidney iron status in passive Heymann nephritis and the effect of an iron-deficient diet
J Am Soc Nephrol
1996
7
1183
1188

8866411


68.
Sumboonnanonda
A

Malasit
P

Tanphaichitr
VS

Ong-ajyooth
S

Petrarat
S

Vongjirad
A


Renal tubular dysfunction in alpha-thalassemia
Pediatr Nephrol
2003
18
257
260

12644919


69.
Zager
RA


Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy
Kidney Int
2005
68
1533
1542

16164630


70.
Mircescu
G

Garneata
L

Capusa
C

Ursea
N


Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients
Nephrol Dial Transplant
2006
21
120
124

16144853


71.
Agarwal
R


Proinflammatory effects of iron sucrose in chronic kidney disease
Kidney Int
2006
69
1259
1263

16609688


72.
Zager
RA

Johnson
AC

Hanson
SY

Wasse
H


Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury
Am J Kidney Dis
2002
40
90
103

12087566


73.
Lim
PS

Wie
YH

Yu
YL

Kho
B


Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy
Nephrol Dial Transplant
1999
14
2680
2687

10534512


74.
Roob
JM

Khoschsorur
G

Tiran
A

Horina
JH

Holzer
H

Winklhofer-Roob
BM


Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis
J Am Soc Nephrol
2000
11
539
549

10703678


75.
Drüeke
T

Witko-Sarsat
V

Massy
Z

Descamps-Latscha
B

Guerin
AP

Marchais
SJ

Gausson
V

London
GM


Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease
Circulation
2002
106
2212
2217

12390950


76.
Anraku
M

Kitamura
K

Shinohara
A

Adachi
M

Suenga
A

Maruyama
T

Miyanaka
K

Miyoshi
T

Shiraishi
N

Nonoguchi
H

Otagiri
M

Tomita
K


Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients
Kidney Int
2004
66
841
848

15253741


77.
Michelis
R

Gery
R

Sela
S

Shurtz-Swirski
R

Grinberg
N

Snitkovski
T

Shasha
SM

Kristal
B


Carbonyl stress induced by intravenous iron during haemodialysis
Nephrol Dial Transplant
2003
18
924
930

12686666


78.
Michelis
R

Sela
S

Kristal
B


Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels
Nephrol Dial Transplant
2005
20
1963
1969

15956071


79.
Scheiber-Mojdehkar
B

Lutzky
B

Schaufler
R

Sturm
B

Goldenberg
H


Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation
J Am Soc Nephrol
2004
15
1648
1655

15153577


80.
Locatelli
F

Canaud
B

Eckardt
KU

Stenvinkel
P

Wanner
C

Zoccali
C


Oxidative stress in end-stage renal disease: an emerging threat to patient outcome
Nephrol Dial Transplant
2003
18
1272
1280

12808161


81.
Kooistra
MP

Kersting
S

Gosriwatana
I

Lu
S

Nijhoff-Schutte
J

Hider
RC

Marx
JJ


Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion
Eur J Clin Invest
2002
32
Suppl 1
36
41

11886430


82.
Schaller
G

Scheiber-Mojdehkar
B

Wolzt
M

Puttinger
H

Mittermayer
F

Hörl
WH

Födinger
M

Sunder-Plassmann
G

Vychytil
A


Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients
Kidney Int
2005
68
2814
2822

16316358


83.
Deicher
R

Ziai
F

Bieglmayer
C

Schillinger
M

Hörl
WH


Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients
J Am Soc Nephrol
2005
16
1811
1818

15814831


84.
Moretti
D

Zimmermann
MB

Wegmuller
R

Walczyk
T

Zeder
C

Hurrell
RF


Iron status and food matrix strongly affect the relative bioavailability of ferric pyrophosphate in humans
Am J Clin Nutr
2006
83
632
638

16522911


85.
Kaltwasser
JP

Werner
E

Niechzial
M


Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations
Arzneimittelforschung
1987
37
122
129

3566867


86.
Domingo
JL

Gomez
M

Llobet
JM

Richart
C


Effect of ascorbic acid on gastrointestinal aluminium absorption
Lancet
1991
338
1467

1683458


87.
Attallah
N

Osman-Malik
Y

Frinak
S

Besarab
A


Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia
Am J Kidney Dis
2006
47
644
654

16564942


88.
Tarng
DC

Hung
SC

Huang
TP


Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients
J Am Soc Nephrol
2004
15
2486
2493

15339999


89.
Fumeron
C

Nguyen-Khoa
T

Saltiel
C

Kebede
M

Buisson
C

Drueke
TB

Lacour
B

Massy
ZA


Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients
Nephrol Dial Transplant
2005
20
1874
1879

15972322


90.
Keven
K

Kutlay
S

Nergizoglu
G

Erturk
S


Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients
Am J Kidney Dis
2003
41
1233
1239

12776276


91.
Chan
D

Irish
A

Dogra
G


Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients
Nephrology (Carlton)
2005
10
336
340

16109077


92.
Sturm
B

Laggner
H

Ternes
N

Goldenberg
H

Scheiber-Mojdehkar
B


Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron
Kidney Int
2005
67
1161
1170

15698458


93.
Tarng
DC

Huang
TP


A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload
Nephrol Dial Transplant
1998
13
2867
2872

9829492


94.
Gastaldello
K

Vereerstraeten
A

Nzame-Nze
T

Vanherweghem
JL

Tielemans
C


Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration
Nephrol Dial Transplant
1995
10
Suppl 6
44
47

8524494


95.
Giancaspro
V

Nuzziello
M

Pallotta
G

Sacchetti
A

Petrarulo
F


Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial
J Nephrol
2000
13
444
449

11132761


96.
Sezer
S

Ozdemir
FN

Yakupoglu
U

Arat
Z

Turan
M

Haberal
M


Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients
Artif Organs
2002
26
366
370

11952508


97.
Lin
CL

Hsu
PY

Yang
HY

Huang
CC


Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload
Ren Fail
2003
25
445
453

12803508


98.
Tarng
DC

Wei
YH

Huang
TP

Kuo
BI

Yang
WC


Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia
Kidney Int
1999
55
2477
2486

10354297


99.
Deira
J

Diego
J

Martinez
R

Oyarbide
A

Gonzalez
A

Diaz
H

Grande
J


Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia
J Nephrol
2003
16
703
709

14733417


100.
Canavese
C

Petrarulo
M

Massarenti
P

Berutti
S

Fenoglio
R

Pauletto
D

Lanfranco
G

Bergamo
D

Sandri
L

Marangella
M


Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients
Am J Kidney Dis
2005
45
540
549

15754276


101.
Lorenz
M

Kletzmayr
J

Perschl
A

Furrer
A

Hörl
WH

Sunder-Plassmann
G


Anemia and iron deficiencies among long-term renal transplant recipients
J Am Soc Nephrol
2002
13
794
797

11856787


102.
Yorgin
PD

Scandling
JD

Belson
A

Sanchez
J

Alexander
SR

Andreoni
KA


Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem?
Am J Transplant
2002
2
429
435

12123208


103.
Vanrenterghem
Y

Ponticelli
C

Morales
JM

Abramowicz
D

Baboolal
K

Eklund
B

Kliem
V

Legendre
C

Morais Sarmento
AL

Vincenti
F


Prevalence and management of anemia in renal transplant recipients: a European survey
Am J Transplant
2003
3
835
845

12814475


104.
Mix
TC

Kazmi
W

Khan
S

Ruthazer
R

Rohrer
R

Pereira
BJ

Kausz
AT


Anemia: a continuing problem following kidney transplantation
Am J Transplant
2003
3
1426
1433

14525605


105.
Yorgin
PD

Belson
A

Sanchez
J

Uzri
AY

Sarwal
M

Bloch
DA

Oehlert
J

Salvatierra
O

Alexander
SR


Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients
Am J Kidney Dis
2002
40
1306
1318

12460052


106.
Gillespie
RS

Symons
JM


Sodium ferric gluconate for post-transplant anemia in pediatric and young adult renal transplant recipients
Pediatr Transplant
2005
9
43
46

15667610


107.
Morii
M

Ueno
K

Ogawa
A

Kato
R

Yoshimura
H

Wada
K

Hashimoto
H

Takada
M

Tanaka
K

Nakatani
T

Shibakawa
M


Impairment of mycophenolate mofetil absorption by iron ion
Clin Pharmacol Ther
2000
68
613
616

11180021


108.
Lorenz
M

Wolzt
M

Weigel
G

Puttinger
H

Hörl
WH

Födinger
M

Speiser
W

Sunder-Plassmann
G


Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients
Am J Kidney Dis
2004
43
1098
1103

15168391


109.
Lidgate
D

Brandl
M

Holper
M

Abubakari
A

Wu
X


Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil
Drug Dev Ind Pharm
2002
28
1275
1283

12476873


110.
Coyne
D


Challenging the boundaries of anemia management: a balance approach to i.v. iron and EPO therapy
Kidney Int
2006
69
S1
S3

Coyne D (2006) Challenging the boundaries of anemia management: a balance approach to i.v. iron and EPO therapy. Kidney Int 69:S1–S3 




